Outcomes of an Intravenous to Subcutaneous Infliximab ( CT ‐ P13 ) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study
ACR Open Rheumatology · 2026-01 · 8 (1)
DOI: 10.1002/acr2.70158 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 11.01.2026. Verfasst von Luca Iorio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA).
Methods
We conducted a prospective, single‐center, proof‐of‐concept observational study of consecutive adults with TA in sustained clinical, laboratory, and positron emission tomography (PET) remission switched from stable 5 mg/kg dose IV‐IFX to SC‐IFX 120 mg every two weeks. Assessments at baseline, 6 months, and 12 months included Indian Takayasu Clinical Activity Score (ITAS2010), Disease Extent Index‐Takayasu (Dei.TAK), PET Vascular Activity Score (PETVAS), C‐reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), Large Vessel Vasculitis Index of Damage (LVVID), and safety data. The primary objective was 12‐month drug persistence. Secondary outcomes included remission rates, changes in ITAS2010, Dei.TAK, PETVAS, acute‐phase reactants, damage accrual, and safety.
Results
Nine women (median age 35 [interquartile range (IQR) 28–44] years) were included. The median IV‐IFX exposure before the switch was 60 (IQR 24–72) months. Twelve‐month drug persistence was 77.8%. One patient discontinued early due to an injection‐site reaction, and another experienced a relapse at 12 months that required a therapy change. At 12 months, 87.5% (seven of eight) patients remained in remission. CRP and ESR remained stable ( P = 0.297 and P = 0.068, respectively). PETVAS was similar to pre‐switch values ( P = 0.589). Median LVVID remained stable throughout follow‐up. No serious adverse events occurred.
Conclusions
IV‐IFX to SC‐IFX switching was feasible and well tolerated and generally maintained remission over 12 months in most patients with TA, with stable metabolic imaging and no increase in damage accrual. These findings support SC‐IFX as a practical maintenance strategy, warranting confirmation in larger multicenter cohorts.
Autor:innen und Institutionen
- Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
ORCID-Profile: Luca Iorio, Andrea Doria, Roberto Padoan
Zitieren
APA
Iorio, L., Davanzo, F., Fiorin, E., Codirenzi, M., Prevedello, R., Doria, A., & Padoan, R. (2026). Outcomes of an Intravenous to Subcutaneous Infliximab ( CT ‐ P13 ) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study. ACR Open Rheumatology, 8(1). https://doi.org/10.1002/acr2.70158
Vancouver
Iorio L, Davanzo F, Fiorin E, Codirenzi M, Prevedello R, Doria A, et al. Outcomes of an Intravenous to Subcutaneous Infliximab ( CT ‐ P13 ) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study. ACR Open Rheumatology. 2026;8(1). doi:10.1002/acr2.70158
BibTeX
@article{Iorio2026,
author = {Iorio, Luca and Davanzo, Federica and Fiorin, Eleonora and Codirenzi, Marta and Prevedello, Roberta and Doria, Andrea and Padoan, Roberto},
title = {Outcomes of an Intravenous to Subcutaneous Infliximab ( CT ‐ P13 ) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {1},
doi = {10.1002/acr2.70158}
}
EUVIMED